<DOC>
	<DOCNO>NCT01025778</DOCNO>
	<brief_summary>Despite substantial progress treatment pediatric acute leukemia significant number child experience primary secondary resistance treatment . In word possible achieve remission use standard chemotherapy ( primary resistance ) patient develop chemotherapy resistant relapse ( secondary resistance ) . Children fail achieve remission child relapse previous allogeneic stem cell transplantation short life expectancy palliative treatment still remain reasonable option escalation conventional chemotherapy longer effective . The role Graft versus Leukemia effect postulate one mechanism contribute leukemia control/eradication transplantation hematopoietic stem cell . In study investigator combine intensified multiagent Clofarabine contain chemotherapy post-induction treatment intensification use reduce intensity conditioning follow haploidentical hematopoietic stem cell transplantation . Introducing new drug treatment resistant leukemia investigator want achieve response allow u proceed immediate haploidentical transplantation . Using haploidentical donor investigator avoid time consume search unrelated donor perform transplantation optimal time-point . Combating therapy resistant leukemia investigator would like evoke utilize potential Graft-versus-Leukemia effect much pronounce haploidentical setting , well document allogeneic transplantation match donor effective resistant disease . The use best KIR mismatch donor post-transplant donor lymphocyte infusion implement order develop/intensify graft versus leukemia effect .</brief_summary>
	<brief_title>Haploidentical Stem Cell Transplantation Children With Therapy Resistant Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Target population 1 . Refractory acute lymphoblastic leukemia Chemoresistant isolate combined bone marrow relapse Relapse during/after conventional treatment Relapse ≥6 month allogeneic stem cell transplantation Primary induction failure Isolated extramedullary relapse previous HSCT ( &gt; 6 month ) 2 . Refractory acute myeloblastic leukemia include sAML Chemoresistant relapse Relapse during/after conventional treatment Relapse ≥6 month allogeneic stem cell transplantation Primary induction failure Inclusion criterion start induction treatment multidrug regimen 1 . Age ≥ 1 ≤21 year 2 . Patients previous HCST ≥ 6 3 . Provide sign write informed consent patient ' , patient ' parent /guardians Older child capable understanding investigational nature , potential risk benefit study , able provide valid inform consent well . 4 . Cardiac output SF ≥25 % 5 . Have adequate renal hepatic function indicate follow laboratory value : Calculated creatinine clearance ≥90 ml/min/1.73 m2 Serum bilirubin ≤1.5 X upper limit normal ( ULN ) Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤2.5 X ULN Alkaline phosphatase ≤ 2.5 X ULN 6 . Performance score ≥70 % ( Lansky Karnofsky ) 7 . A suitable haploidentical family member available stem cell donation , &gt; 18 year age , fulfil institutional criterion blood marrow donation . 8 . Male female patient must use effective contraceptive method study minimum 6 month study treatment . Inclusion criterion proceed transplant induction 1 . Cardiac output SF ≥25 % 2 . Have adequate renal hepatic function indicate follow laboratory value : Calculated creatinine clearance ≥90 ml/min/1.73 m2 Serum bilirubin ≤1.5 X upper limit normal ( ULN ) Aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤2.5 X ULN Alkaline phosphatase ≤ 2.5 X ULN 3 . Performance score ≥70 % ( Lansky Karnofsky ) 4 . A suitable haploidentical family member available stem cell donation , &gt; 18 year age , fulfil institutional criterion blood marrow donation . 5 . Capable understanding investigational nature , potential risk benefit study , able provide valid inform consent . 6 . Female patient childbearing potential must negative serum pregnancy test within 2 week prior enrollment . 7 . Male female patient must use effective contraceptive method study minimum 6 month study treatment . 1 . Current concomitant chemotherapy , radiation therapy , immunotherapy specify protocol . 2 . Use investigational agent within 30 day anticancer therapy within 2 week study entry exception hydroxyurea . The patient must recover acute toxicity previous therapy . 3 . Have severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver , organ system may place patient undue risk undergo treatment . 4 . Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . 5 . Pregnant lactating patient . 6 . Any significant concurrent malignant disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Haploidentical hematopoietic stem cell transplantation</keyword>
	<keyword>Graft versus host disease</keyword>
	<keyword>Donor lymphocyte infusion</keyword>
	<keyword>Graft versus leukemia effect</keyword>
	<keyword>Immunological recovery</keyword>
	<keyword>Bridge transplant approach</keyword>
	<keyword>Therapy resistant leukemia</keyword>
	<keyword>Hematological malignancy</keyword>
</DOC>